Difference between revisions of "Apatinib (Aitan)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Chemotherapeutic" to "")
m (Text replacement - "Category:Kinase inhibitors" to "")
Line 15: Line 15:
 
[[Category:Oral medications]]
 
[[Category:Oral medications]]
  
[[Category:Kinase inhibitors]]
+
 
 
[[Category:VEGFR inhibitors]]
 
[[Category:VEGFR inhibitors]]
 
[[Category:KIT inhibitors]]
 
[[Category:KIT inhibitors]]

Revision as of 23:07, 28 February 2020

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.

Diseases for which it is used

Also known as

  • Code name: YN968D1
  • Generic name: rivoceranib
  • Brand name: Aitan